Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice

Proteomics

Volumn 8, Issue 13, 2008, Pages 2651-2664

  Martínez López, Raquel ^a   Nombela, César ^a   Diez Orejas, Rosalía ^a   Monteoliva, Lucía ^a   Gil, Concha ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

C. albicans; Cell wall mutant; Immunoproteomics; Surface proteins; Vaccination

Indexed keywords

5 METHYLTETRAHYDROPTEROYLTRIGLUTAMATE HOMCYSTEINE METHYLTRANSFERASE 6; ANTIBODY; CANDIDA ALBICANS VACCINE; CELL MEMBRANE PROTEIN; CITRATE SYNTHASE; CYSTATHIONINE BETA SYNTHASE; ELONGATION FACTOR; F1F0 ATPASE COMPLEX FL ALPHA SUBUNIT; F1F0 ATPASE COMPLEX FL BETA SUBUNIT; FUNGAL PROTEIN; PHOSPHOGLUCONATE DEHYDROGENASE; PHOSPHOGLUCONATE DEHYDROGENASE 1; PROTEIN ECM33; PROTEOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RIBOSOMAL PROTEIN L10; RIBOSOMAL PROTEIN YST1; RIBOSOME PROTEIN; TRANSKETOLASE; TRANSKETOLASE 1; TRANSLATION ELONGATION FACTOR 2; TRANSLATION ELONGATION FACTOR EEFLBETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; BAGG ALBINO MOUSE; CANDIDA ALBICANS; CELL WALL; CONTROLLED STUDY; FEMALE; FUNGAL CELL; FUNGAL STRAIN; FUNGAL VIRULENCE; IMMUNOBLOTTING; IMMUNOGENICITY; INVASIVE CANDIDIASIS; MOUSE; MOUSE MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; VACCINATION; WILD TYPE;

ANIMALS; ANTIGENS, FUNGAL; CANDIDA ALBICANS; CANDIDIASIS; CELL WALL; FEMALE; FUNGAL VACCINES; MICE; MICE, INBRED BALB C; MODELS, IMMUNOLOGICAL; MUTATION; PROTEOMICS; VACCINATION;

CANDIDA ALBICANS; MUS;

EID: 47249158622     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200701056     Document Type: Article

References (64)

1. Bodey, G. P., What's new in fungal infection in leukemic patients. Leuk. Lymphoma 1993, 11, 127-135.
2. Calderone, R. A., in: Calderone, R. A. (Ed.), Taxonomy and Biology of Candida in Candida and Candidiasis, ASM Press, Washington, D.C. 2002, pp. 15-27.
3. Pfaller, M. A., Messer, S. A., Houston, A., Rangel-Frausto, M. S. et al., National epidemiology of mycoses survey: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn. Microbiol. Infect Dis. 1998, 31, 289-296.
4. Rentz, A. M., Halpern, M. T., Bowden, R., The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect Dis. 1998, 27, 781-788.
5. Wey, S. B., Mori, M., Pfaller, M. A., Woolson, R. F. et al., Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. 1988, 148, 2642-2645.
6. Viudes, A., Peman, J., Canton, E., Ubeda, P. et al., Candidemia at a tertiary-care hospital: Epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21, 767-774.
7. Casadevall, A., Pirofski, L. A., Adjunctive immune therapy for fungal infections. Clin. Infect. Dis. 2001, 33, 1048-1056.
8. Deepe, G. S., Jr., Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 1997, 10, 585-596.
9. Dixon, D. M., Casadevall, A., Klein, B., Mendoza, L. et al., Development of vaccines and their use in the prevention of fungal infections. Med. Mycol. 1998, 36, 57-67.
10. Dan, J. M., Levitz, S. M., Prospects for development of vaccines against fungal diseases. Drug Resist. Updat. 2006, 9, 105-110.
11. Lemos, J. A., Giambiagi-Demarval, M., Castro, A. C., Expression of heat-shock proteins in Streptococcus pyogenes and their immunoreactivity with sera from patients with streptococcal diseases. J. Med. Microbiol. 1998, 47, 711-715.
12. Teixeira-Gomes, A. P., Cloeckaert, A., Bezard, G., Bowden, R. A. et al., Identification and characterization of Brucella ovis immunogenic proteins using two-dimensional electrophoresis and immunoblotting. Electrophoresis 1997, 18, 1491-1497.
13. Delvecchio, V. G., Connolly, J. P., Alefantis, T. G., Walz, A. et al., Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis. Appl. Environ. Microbiol. 2006, 72, 6355-6363.
14. Harris, J. B., Baresch-Bernal, A., Rollins, S. M., Alam, A. et al., Identification of in vivo-induced bacterial protein antigens during human infection with Salmonella enterica serovar Typhi. Infect. Immun. 2006, 74, 5161-5168.
15. Britton, S., Papp-Szabo, E., Simala-Grant, J., Morrison, L. et al., A novel Helicobacter pylori cell-surface polysaccharide. Carbohydr. Res. 2005, 340, 1605-1611.
16. Lopez-Ribot, J. L., Casanova, M., Murgui, A., Martinez, J. P., Antibody response to Candida albicans cell wall antigens. FEMS Immunol. Med. Microbiol. 2004, 41, 187-196.
17. Fernandez-Arenas, E., Molero, G., Nombela, C., Diez-Orejas, R. et al., Low virulent strains of Candida albicans: Unravelling the antigens for a future vaccine. Proteomics 2004, 4, 3007-3020.
18. Fernandez-Arenas, E., Molero, G., Nombela, C., Diez-Orejas, R. et al., Contribution of the antibodies response induced by a low virulent Candida albicans strain in protection against systemic candidiasis. Proteomics 2004, 4, 1204-1215.
19. Cid, V. J., Duran, A., del Rey, F., Snyder, M. P. et al., Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Microbiol. Rev. 1995, 59, 345-386.
20. Martinez-Lopez, R., Monteoliva, L., Diez-Orejas, R., Nombela, C. et al., The GPI-anchored protein CaEcm33p is required for cell wall integrity, morphogenesis and virulence in Candida albicans. Microbiology 2004, 150, 3341-3354.
21. Martinez-Lopez, R., Park, H., Myers, C. L., Gil, C. et al., Candida albicans Ecm33p is important for normal cell wall architecture and interactions with host cells. Eukaryot. Cell. 2006, 5, 140-147.
22. Gillum, A. M., Tsay, E. Y., Kirsch, D. R., Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 1984, 198, 179-182.
23. Diez-Orejas, R., Molero, G., Navarro-Garcia, F., Pla, J. et al., Reduced virulence of Candida albicans MKC1 mutants: A role for mitogen-activated protein kinase in pathogenesis. Infect. Immun. 1997, 65, 833-837.
24. Diez-Orejas, R., Molero, G., Rios-Serrano, I., Vazquez, A. et al., Low virulence of a morphological Candida albicans mutant. FEMS Microbiol. Lett. 1999, 176, 311-319.
25. Pitarch, A., Pardo, M., Jimenez, A., Pla, J. et al., Two-dimensional gel electrophoresis as analytical tool for identifying Candida albicans immunogenic proteins. Electrophoresis 1999, 20, 1001-1010.
26. Pitarch, A., Sanchez, M., Nombela, C., Gil, C., Analysis of the Candida albicans proteome. II. Protein information technology on the Net (update 2002). J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 787, 129-148.
27. Bjellqvist, B., Sanchez, J. C., Pasquali, C., Ravier, F. et al., Micropreparative two-dimensional electrophoresis allowing the separation of samples containing milligram amounts of proteins. Electrophoresis 1993, 14, 1375-1378.
28. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
29. Pitarch, A., Diez-Orejas, R., Molero, G., Pardo, M. et al., Analysis of the serologic response to systemic Candida albicans infection in a murine model. Proteomics 2001, 1, 550-559.
30. Sechi, S., Chait, B. T., Modification of cysteine residues by alkylation. A tool in peptide mapping and protein identification. Anal. Chem. 1998, 70, 5150-5158.
31. d'Enfert, C., Goyard, S., Rodriguez-Arnaveilhe, S., Frangeul, L. et al., CandidaDB: A genome database for Candida albicans pathogenomics. Nucleic Acids Res. 2005, 33, D353-D357.
32. Arnaud, M. B., Costanzo, M. C., Skrzypek, M. S., Binkley, G. et al., The Candida Genome Database (CGD), a community resource for Candida albicans gene and protein information. Nucleic Acids Res. 2005, 33, D358-D363.
33. Braun, B. R., van Het, H. M., d'Enfert, C., Martchenko, M. et al., A human-curated annotation of the Candida albicans genome. PLoS Genet. 2005, 1, 36-57.
34. Krah, A., Jungblut, P. R., Immunoproteomics. Methods Mol. Med. 2004, 94, 19-32.
35. Pitarch, A., Nombela, C., Gil, C., Candida albicans biology and pathogenicity: Insights from proteomics. Methods Biochem. Anal. 2006, 49, 285-330.
36. Haas, G., Karaali, G., Ebermayer, K., Metzger, W. G. et al., Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2002, 2, 313-324.
37. Hess, J. L., Blazer, L., Romer, T., Faber, L. et al., Immunoproteomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 815, 65-75.
38. Pedersen, S. K., Sloane, A. J., Prasad, S. S., Sebastian, L. T. et al., An immunoproteomic approach for identification of clinical biomarkers for monitoring disease: Application to cystic fibrosis. Mol. Cell. Proteomics 2005, 4, 1052-1060.
39. Cardenas-Freytag, L., Cheng, E., Mayeux, P., Domer, J. E. et al., Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immun. 1999, 67, 826-833.
40. Londono, L. P., Jones, H. B., Vie, A. T., McPheat, W. L. et al., Characterisation of Candida albicans infections of haematogenous and mucosal origin in mice lacking the interferon gamma receptor protein. FEMS Immunol. Med. Microbiol. 2000, 27, 117-125.
41. Pardo, M., Monteoliva, L., Vazquez, P., Martinez, R. et al., PST1 and ECM33 encode two yeast cell surface GPI proteins important for cell wall integrity. Microbiology 2004, 150, 4157-4170.
42. Rodriguez-Ortega, M. J., Norais, N., Bensi, G., Liberatori, S. et al., Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat. Biotechnol. 2006, 24, 191-197.
43. Mochon, A. B., Cutler, J. E., Is a vaccine needed against Candida albicans? Med. Mycol. 2005, 43, 97-115.
44. Pitarch, A., Jimenez, A., Nombela, C., Gil, C., Decoding serological response to Candida cell wall immunome into novel diagnostic, prognostic, and therapeutic candidates for systemic candidiasis by proteomic and bioinformatic analyses. Mol. Cell. Proteomics 2006, 5, 79-96.
45. Pachl, J., Svoboda, P., Jacobs, F., Vandewoude, K. et al., A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 2006, 42, 1404-1413.
46. Cassone, A., De Bernardis, F., Torososantucci, A., An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr. Mol. Med. 2005, 5, 377-382.
47. Pirofski, L., Casadevall, A., in: Heitman, J., Filler, S. G., Edwards, J. E. Jr., Mitchell, A. P. (Eds.), Molecular Principles of Fungal Pathogenesis, ASM Press, Washington, D.C. 2006, pp. 487-504.
48. Romani, L., Mocci, S., Bietta, C., Lanfaloni, L. et al., Th1 and Th2 cytokine secretion patterns in murine candidiasis: Association of Th1 responses with acquired resistance. Infect. Immun. 1991, 59, 4647-4654.
49. Thomas, D. P., Viudes, A., Monteagudo, C., Lazzell, A. L. et al., A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics 2006, 6, 6033-6041.
50. Fernandez-Arenas, E., Cabezon, V., Bermejo, C., Arroyo, J. et al., Integrated proteomics and genomics strategies bring new insight into Candida albicans response upon macrophage interaction. Mol. Cell. Proteomics 2007, 6, 460-478.
51. Bruneau, J. M., Maillet, I., Tagat, E., Legrand, R. et al., Drug induced proteome changes in Candida albicans: Comparison of the effect of beta(1,3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. Proteomics 2003, 3, 325-336.
52. Fradin, C., Kretschmar, M., Nichterlein, T., Gaillardin, C. et al., Stage-specific gene expression of Candida albicans in human blood. Mol. Microbiol. 2003, 47, 1523-1543.
53. Eckstein, M., Barenholz, Y., Bar, L. K., Segal, E., Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice. Vaccine 1997, 15, 220-224.
54. Mallick, A. I., Singha, H., Chaudhuri, P., Nadeem, A. et al., Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection. Vaccine 2007, 25, 3692-3704.
55. Zhang, H., Lee, E. G., Liao, M., Compaore, M. K. et al., Identification of ribosomal phosphoprotein P0 of Neospora caninum as a potential common vaccine candidate for the control of both neosporosis and toxoplasmosis. Mol. Biochem. Parasitol. 2007, 153, 141-148.
56. Terkawi, M. A., Jia, H., Zhou, J., Lee, E. G. et al., Babesia gibsoni ribosomal phosphoprotein P0 induces cross-protective immunity against B. microti infection in mice. Vaccine 2007, 25, 2027-2035.
57. Terkawi, M. A., Jia, H., Gabriel, A., Goo, Y. K. et al., A shared antigen among Babesia species: Ribosomal phosphoprotein P0 as a universal babesial vaccine candidate. Parasitol. Res. 2007 102, 35-40.
58. Rajeshwari, K., Patel, K., Nambeesan, S., Mehta, M. et al., The P domain of the P0 protein of Plasmodium falciparum protects against challenge with malaria parasites. Infect. Immun. 2004, 72, 5515-5521.
59. Spence, J. M., Clark, V. L., Role of ribosomal protein L12 in gonococcal invasion of Hec1B cells. Infect. Immun. 2000, 68, 5002-5010.
60. Stober, C. B., Lange, U. G., Roberts, M. T., Gilmartin, B. et al., From genome to vaccines for leishmaniasis: Screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 2006, 24, 2602-2616.
61. Iborra, S., Carrion, J., Anderson, C., Alonso, C. et al., Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect. Immun. 2005, 73, 5842-5852.
62. Singh, S., Sehgal, A., Waghmare, S., Chakraborty, T. et al., Surface expression of the conserved ribosomal protein P0 on parasite and other cells. Mol. Biochem. Parasitol. 2002, 119, 121-124.
63. Pitarch, A., Abian, J., Carrascal, M., Sanchez, M. et al., Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. Proteomics 2004, 4, 3084-3106.
64. Martinez, J. P., Gil, M. L., Lopez-Ribot, J. L., Chaffin, W. L., Serologic response to cell wall mannoproteins and proteins of Candida albicans. Clin. Microbiol. Rev. 1998, 11, 121-141.